Formulation Technologies for the Development of Dry Powders for Inhalation
Summary: Pulmonary and nasal delivery are the preferred routes of administration for the majority of locally acting drugs exerting their effects on the airways or nasal mucosa. For both routes of administration, molecules are most often highly potent small molecules. Pulmonary products are primarily delivered via metered dose inhalers, Dry Powder Inhalers (DPIs) with carrier-based formulations, or nebulized solutions; nasal products are delivered as liquid solutions or suspensions. Drug pipelines have now expanded to include inhaled high-dose products, biotherapeutics (peptides, proteins, gene therapies, and phages), and systemically acting therapeutics, which serve as alternatives to intravenous and sub-cutaneous injected dosage forms. New technologies, such as spray drying, are gaining traction to address the complexity of delivering these molecules through the pulmonary or nasal routes. This webinar will discuss challenges and key considerations for spray-dried formulations for inhalation, along with a review of current technologies and approved products utilizing particle engineering approaches.